Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|ANHL1131||COG||Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients||Pediatric CIRB||Available to Open|
|ADVL06B1||COG||A Pharmacokinetic-Pharmacodynamic-Pharmacogenetic Study of Actinomycin-D and Vincristine in Children with Cancer: A Group-Wide Non-Therapeutic Study||Pediatric CIRB||Completed|
|AAML1331||COG||A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid: A COG Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|AALL1631||COG||International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones||Pediatric CIRB||Available to Open|
|PBTC-055||PBTC||Phase I/II trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF fusion/duplication positive or NF1-associated recurrent or progressive gliomas in children and young adults||Pediatric CIRB||Available to Open|
|ARAR0332||COG||Treatment of Adrenocortical Tumors with Surgery plus Lymph Node Dissection and Multiagent Chemotherapy: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|ACCL1033||COG||A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL: A Group-wide Non-Therapeutic Study||Pediatric CIRB||Available to Open|
|AALL05B1||COG||A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens||Pediatric CIRB||Available to Open|
|ANBL09P1||COG||A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma: A Limited Institution Pilot Study||Pediatric CIRB||Available to Open|
|ACNS1022||COG||A Phase II Randomized Trial of Lenalidomide (NSC # 703813; IND # 70116) in Pediatric Patients with Recurrent; Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas: A Groupwide Phase II Study||Pediatric CIRB||Available to Open|